ProCE Banner Activity

RNA Interference: An Investigational Strategy for HBV Reported at EASL 2023

Clinical Thought

Data reported at EASL 2023 provided early data on efficacy and duration of response with at least 2 types of regimens including RNA interference agents.

Released: August 16, 2023

Share

Faculty

Tarik Asselah

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France

Tarik Asselah, MD, PhD: consultant/advisor/speaker: Antios, Eiger, Enyo, Janssen, Gilead, GlaxoSmithKline, Roche, Vir Biotechnology.